The one-time gene therapy treatment is priced at $2.1 million and is designed to treat spinal muscular atrophy in infants.
Novartis said about 200 patients have been treated with Zolgensma since it launched last June, according to STAT.
The drug is covered for 97 percent of patients with commercial plans; 50 percent of Medicaid patients are covered.
Read the full article here.
More articles on pharmacy:
Drug shortages update: 5 things to know
Grocery store pharmacies across the country finding it harder to stay in business
AbbVie to donate $1M of drug China says will combat coronavirus
